Phase III Trial Confirms Eneboparatide’s Potential for Hypoparathyroidism Treatment

Promising results from the CALYPSO Phase III trial reveal that eneboparatide (AZP-3601) has successfully met its primary endpoint for treating chronic hypoparathyroidism (HypoPT). The investigational parathyroid hormone receptor 1 agonist helped patients achieve normal calcium levels without the need for active vitamin D and oral calcium therapy, marking a significant advancement for those affected by this rare endocrine disorder. With over 200,000 individuals in the U.S. and EU living with HypoPT, eneboparatide offers a potential new treatment path for patients struggling with the condition’s impact on calcium and phosphate regulation.

According to Marc Dunoyer, CEO of Alexion, AstraZeneca Rare Disease, these results highlight eneboparatide’s potential to improve outcomes for HypoPT patients, who often face complications like osteoporosis and kidney issues. The treatment was well tolerated during the 24-week trial, and all patients will continue receiving eneboparatide in a long-term extension phase. Full data at 52 weeks will provide further insights into its safety and efficacy, with Alexion planning to present findings at upcoming medical conferences and engage with health authorities for regulatory discussions.